Rezafungin for Treatment of Invasive Candidiasis

George R. Thompson III, MD
Associate Professor
Division of Infectious Diseases
Department of Internal Medicine
Department of Medical Microbiology and Immunology
University of California-Davis Medical Center

UCDAVIS
UNIVERSITY OF CALIFORNIA

Disclosures / Acknowledgments

- **G. R. Thompson**: Cidara Therapeutics (investigator, research support); Mayne (investigator, research support); Astellas (consultant, investigator, consulting fee, research support); Scynexis (investigator, research support); Vical (consultant, consulting fee)
- Editorial support was provided by T. Chung (Scribant Medical) and funded by Cidara Therapeutics.

STRIVE Phase 2 Trial of Rezafungin Treatment

Documented Candidemia & Invasive Candidiasis



Objectives

To establish:

- Safety and tolerability
- Clinical and mycological efficacy across timepoints
- Efficacy vs caspofungin
- Dosing regimen for Phase 3

Clinicaltrials.gov; NCT02734862

Demographics and Baseline Characteristics

ITT Population

Parameter	Rezafungin 400 mg Wk 1 / 400 mg QWk N=81	Rezafungin 400 mg Wk1 / 200 mg QWk N=57	Caspofungin 70 mg Day 1 / 50 mg QD N=69
Age, Mean [Range]	60 y [24-88]	60 y [24-91]	59 y [24-93]
Diagnosis			
Candidemia	76.5%	80.7%	81.2%
IC	23.5%	19.3%	18.8%
APACHE II[a]			
0-9	28.4%	26.3%	24.6%
10-19	48.1%	45.6%	53.6%
≥20	21.0%	24.6%	13.0%
Mean score	13.4	14.1	14.0

[a]Subjects with scores not calculated/missing not shown.

Candida Species at Enrollment

mITT Population



C. fermentati, C. intermedia, C. kefyr, C. metapsilosis, C. rugosa, C. utilis (n=1 each), and *C. guilliermondii* (n=2)

Non-*albicans* spp. ~54% of baseline isolates

Total number of isolates: 196

Primary Outcome: Overall Response

Day 14 – mITT Population

Overall Response n (%)	Rezafungin 400 mg Wk 1 / 400 mg QWk N=76	Rezafungin 400 mg Wk1 / 200 mg QWk N=46	Caspofungin 70 mg Day 1 / 50 mg QD N=61
Success	46 (60.5)	35 (76.1)	41 (67.2)
Failure	20 (26.3)	8 (17.4)	17 (27.9)

Overall Response = mycological success AND resolution of signs attributable to candidemia/IC

Indeterminate outcomes (those unable to be assessed due to missing data point[s]) not shown.
mITT = microbiological intent-to-treat (all who received study drug and had documented *Candida* infection).

Summary of Rezafungin Efficacy Results

mITT Population



PI Assessment of Clinical Response by *Candida* spp.

Day 14 – mITT Population



Overall Response
Day 5 – mITT Population

Overall Response n (%)	Rezafungin 400 mg Wk1/ 400 mg QWk N=76	Rezafungin 400 mg Wk1/ 200 mg QWk N=46	All Rezafungin (Pooled) N=122	Caspofungin 70 mg Day 1 50 mg QD N=61
Success	42 (55.3)	34 (73.9)	76 (62.3)	34 (55.7)
Failure	24 (31.6)	10 (21.7)	34 (27.9)	24 (39.3)

Day 5 outcomes reflect the initial dose of 400 mg in both RZF-treated arms

Indeterminate outcomes (those unable to be assessed due to missing data point[s]) not shown.
mITT = microbiological intent-to-treat (all who received study drug and had documented *Candida* infection).

Mycological Response

Day 14 – mITT Population (Patients with Candidemia Only)

Mycological Response n (%)	Rezafungin 400 mg Wk 1 / 400 mg QWk N=57	Rezafungin 400 mg Wk1 / 200 mg QWk N=36	Caspofungin 70 mg Day 1 / 50 mg QD N=48
Success	38 (66.7)	25 (69.4)	32 (66.7)
Failure	14 (24.6)	8 (22.2)	14 (29.2)

Indeterminate outcomes (those unable to be assessed due to missing data point[s]) not shown.
mITT = microbiological intent-to-treat (all who received study drug and had documented *Candida* infection).

Summary of Adverse Events

Safety Population

Adverse Event n (%)	Rezafungin 400 mg Wk1/ 400 mg QWk N=81	Rezafungin 400 mg Wk1/ 200 mg QWk N=53	Rezafungin (Pooled) N=134	Caspofungin 70 mg Day 1 50 mg QD N=68
≥1 TEAE	71 (87.7)	49 (92.5)	120 (89.6)	55 (80.9)
Severe	29 (35.8)	17 (32.1)	46 (34.3)	26 (38.2)
Study drug–related	7 (8.6)	6 (11.3)	13 (9.7)	9 (13.2)
TEAE leading to study D/C	6 (7.4)	1 (1.9)	7 (5.2)	4 (5.9)
Serious AE	35 (43.2)	28 (52.8)	63 (47.0)	29 (42.6)
Study drug–related	1 (1.2)	1 (1.9)	2 (1.5)	2 (2.9)

D/C=discontinuation; TEAE (treatment-emergent adverse event)=AE that occurs after first dose of study drug is administered.

Treatment-Emergent Adverse Events (≥10%)

Safety Population

Preferred Term n (%)	Rezafungin 400 mg Wk1/400 mg QWk N=81	Rezafungin 400 mg Wk1/200 mg QWk N=53	Rezafungin (Pooled) N=134	Caspofungin 70 mg Day 1/ 50 mg QD N=68
Hypokalemia	13 (16.0)	9 (17.0)	22 (16.4)	9 (13.2)
Diarrhea	7 (8.6)	11 (20.8)	18 (13.4)	10 (14.7)
Vomiting	6 (7.4)	8 (15.1)	14 (10.4)	5 (7.4)
Pyrexia	9 (11.1)	4 (7.5)	13 (9.7)	6 (8.8)
Anemia	6 (7.4)	7 (13.2)	13 (9.7)	4 (5.9)
Nausea	4 (4.9)	8 (15.1)	12 (9.0)	6 (8.8)
Abdominal Pain	5 (6.2)	6 (11.3)	11 (8.2)	5 (7.4)
Septic Shock	9 (11.1)	1 (1.9)	10 (7.5)	3 (4.4)

Ongoing Phase 3 ReSTORE Trial

Rezafungin Treatment of Candidemia & Invasive Candidiasis



Summary

- ✓ **STRIVE findings which established rezafungin**
  - Clinical safety and tolerability
  - Efficacy (clinical and mycological) across time points and versus caspofungin
  - Once weekly dosing of 400 mg Week 1 / 200 mg Qweek

- ✓ **Results of STRIVE support ongoing phase 3 development** of rezafungin for treatment of candidemia and invasive candidiasis and prophylaxis of IFI

- ✓ Stop by poster #436 on Sunday for more details on STRIVE